Prevymis
New Indication for Prevymis to Prevent CMV in High-Risk Kidney Transplant Recipients
The FDA granted a new indication for letermovir for prophylaxis of CMV disease in high-risk adult kidney transplant ...
JUNE 6, 2023
Prevymis Gets Priority Review for New Indication Decision
Merck is seeking two new indications for Prevymis against cytomegalovirus in transplant patients.
FEBRUARY 17, 2023
Letermovir Prophylaxis Lowers CMV Risk in HCT Patients
The recently approved antiviral drug letermovir (Prevymis, Merck) significantly lowered the risk for clinically ...
APRIL 6, 2018
FDA Approves Prevymis to Prevent CMV Among Stem Cell Transplant Patients
The FDA approved Merck's Prevymis, Merck for prophylaxis of cytomegalovirus infection and disease in adult ...
NOVEMBER 9, 2017
Load more